Selinexor in multiple myeloma

References

• Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086–1107.
   PubMed Web of Science ®Google Scholar
• Guerrero-Garcia TA, Gandolfi S, Laubach JP, et al. The power of proteasome inhibition in multiple myeloma. Expert Rev Proteomics. 2018;15(12):1033–1052. doi: 10.1080/14789450.2018.1543595
   PubMed Web of Science ®Google Scholar
• Gentile M, Offidani M, Vigna E, et al. Ixazomib for the treatment of multiple myeloma. Expert Opin Investig Drugs. 2015;24(9):1287–1298. doi: 10.1517/13543784.2015.1065250.
   PubMed Web of Science ®Google Scholar
• Martino EA, Conticello C, Zamagni E, et al. Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials. Hematol Oncol. 2022 Dec;40(5):1009–1019. doi: 10.1002/hon.3035
   PubMed Web of Science ®Google Scholar
• Raza S, Safyan RA, Lentzsch S. Immunomodulatory drugs (IMiDs) in multiple myeloma. Curr Cancer Drug Targets. 2017;17(9):846–857.
   PubMed Web of Science ®Google Scholar
• Uccello G, Petrungaro A, Mazzone C, et al. Pomalidomide in multiple myeloma. Expert Opin Pharmacother. 2017 Feb;18(2):133–137. doi: 10.1080/14656566.2016.1274973.
   PubMed Web of Science ®Google Scholar
• Cipkar C, Chen C, Trudel S. Antibodies and bispecifics for multiple myeloma: effective effector therapy. Hematology Am Soc Hematol Educ Program. 2022;2022(1):163–172.
   PubMedGoogle Scholar
• Martino EA, Bruzzese A, Iaccino E, et al. Isatuximab in multiple myeloma. Expert Opin Biol Ther. 2023 Apr 4;23(4):315–318. doi: 10.1080/14712598.2023.2193289. Epub 2023 Mar 24.Erratum in: Expert Opin Biol Ther. 2023 Jul-Dec; 23 (9):i. PMID: 36943846.
   PubMed Web of Science ®Google Scholar
• Bruzzese A, Martino EA, Vigna E, et al. Elotuzumab in multiple myeloma. Expert Opin Biol Ther. 2023 Jan;23(1):7–10. doi: 10.1080/14712598.2022.2145882
   PubMed Web of Science ®Google Scholar
• Gentile M, Vigna E, Palmieri S, et al. Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials. Haematologica. 2024 Jan 1;109(1):245–255.
   PubMed Web of Science ®Google Scholar
• Bruzzese A, Derudas D, Galli M, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials. Hematol Oncol. 2022 Oct;40(4):704–715. doi: 10.1002/hon.3031
   PubMed Web of Science ®Google Scholar
• Gentile M, Specchia G, Derudas D, et al. Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials. Haematologica. 2021 Jan 1;106(1):291–294. doi: 10.3324/haematol.2019.241513
   PubMed Web of Science ®Google Scholar
• Parikh RH, Lonial S. Chimeric antigen receptor T-cell therapy in multiple myeloma: a comprehensive review of current data and implications for clinical practice. CA Cancer J Clin. 2023;73(3):275–285.
   PubMed Web of Science ®Google Scholar
• Martino EA, Bruzzese A, Labanca C, et al. Teclistamab-cqyv in multiple myeloma. Eur J Haematol. 2024 Mar;112(3):320–327. doi: 10.1111/ejh.14121
   PubMed Web of Science ®Google Scholar
• Martino EA, Bruzzese A, Iaccino E, et al. Belantamab mafodotin in multiple myeloma. Expert Opin Biol Ther. 2023 Jul-Dec;23(11):1043–1047. doi: 10.1080/14712598.2023.2218543
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Moreau P, Terpos E, et al. Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up (dagger). Ann Oncol. 2021;32(3):309–322. doi: 10.1016/j.annonc.2020.11.014
   PubMed Web of Science ®Google Scholar
• Joseph NS, Kaufman JL, Dhodapkar MV, et al. Long-term follow-up results of lenalidomide, bortezomib, and dexamethasone induction therapy and risk-adapted maintenance approach in newly diagnosed multiple myeloma. J Clin Oncol. 2020 Jun 10 38(17):1928–1937. doi: 10.1200/JCO.19.02515
   PubMed Web of Science ®Google Scholar
• Gengenbach L, Graziani G, Reinhardt H, et al. Choosing the right therapy for patients with relapsed/refractory multiple myeloma (RRMM) in consideration of patient-, disease- and treatment-related factors. Cancers (Basel). 2021;13(17):4320. doi: 10.3390/cancers13174320
   PubMed Web of Science ®Google Scholar
• Stalker ME, Mark TM. Clinical management of triple-class refractory multiple myeloma: a review of current strategies and emerging therapies. Curr Oncol. 2022;29(7):4464–4477. doi: 10.3390/curroncol29070355
   PubMed Web of Science ®Google Scholar
• Gill SK, Unawane R, Wang S, et al. I-open: inferior outcomes of penta-refractory compared to penta-exposed multiple myeloma patients. Blood Cancer J. 2022;12(9):138. doi: 10.1038/s41408-022-00733-2
   PubMed Web of Science ®Google Scholar
• Parikh K, Sekhri A, Cang S, et al. Selective inhibitors of nuclear export (SINE) a novel class of anti-cancer agents. J Hematol Oncol. 2014;7(1):78. doi: 10.1186/s13045-014-0078-0
   PubMedGoogle Scholar
• Grosicki S, Simonova M, Spicka I, et al. Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (Boston): a randomised, open-label, phase 3 trial. Lancet. 2020;396(10262):1563–1573.
   PubMed Web of Science ®Google Scholar
• Chari A, Vogl DT, Gavriatopoulou M, et al. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma. N Engl J Med. 2019;381(8):727–738. doi: 10.1056/NEJMoa1903455
   PubMed Web of Science ®Google Scholar
• Xu D, Grishin NV, Chook YM. NESdb: a database of NES-containing CRM1 cargoes. Mol Biol Cell Am Soc Cell Bio. 2012;23(18):3673–3676.
   PubMed Web of Science ®Google Scholar
• Fung HY, Chook YM. Atomic basis of CRM1-cargo recognition, release and inhibition. Semin Cancer Biol. 2014;27:52–61.
   PubMed Web of Science ®Google Scholar
• Gandhi UH, Senapedis W, Baloglu E, et al. Clinical implications of targeting XPO1-mediated nuclear export in multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(5):335–345. doi: 10.1016/j.clml.2018.03.003
   PubMed Web of Science ®Google Scholar
• Huang ZL, Gao M, Li QY, et al. Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus. Oncotarget. 2013 Dec;4(12):2249–2260. doi: 10.18632/oncotarget.1339
   PubMedGoogle Scholar
• Oloumi A, MacPhail SH, Johnston PJ, et al. Changes in subcellular distribution of topoisomerase II alpha correlate with etoposide resistance in multicell spheroids and xenograft tumors. Cancer Res. 2000 Oct 15;60(20):5747–5753.
   PubMed Web of Science ®Google Scholar
• Culjkovic-Kraljacic B, Baguet A, Volpon L, et al. The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation. Cell Rep. 2012 Aug 30;2(2):207–215. doi: 10.1016/j.celrep.2012.07.007
   PubMed Web of Science ®Google Scholar
• Gravina GL, Senapedis W, McCauley D, et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7(1):85. doi: 10.1186/s13045-014-0085-1
   PubMedGoogle Scholar
• Turner JG, Sullivan DM. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem. 2008;15(26):2648–2655.
   PubMed Web of Science ®Google Scholar
• Selinexor NDA [Internet]. 2024 Jan 6 [cited 2024 Jan 6]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf
   Google Scholar
• Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28(1):155–165. doi: 10.1038/leu.2013.115
   PubMed Web of Science ®Google Scholar
• Argueta C, Kashyap T, Klebanov B, et al. Selinexor synergizes with dexamethasone to repress mTORC1 signaling and induce multiple myeloma cell death. Oncotarget. 2018;9(39):25529–25544. doi: 10.18632/oncotarget.25368
   PubMedGoogle Scholar
• Kashyap T, Argueta C, Aboukameel A, et al. Selinexor, a selective inhibitor of nuclear export (SINE) compound, acts through NFκB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 2016;7(48):78883–78895. doi: 10.18632/oncotarget.12428
   PubMedGoogle Scholar
• Abdul Razak AR, Maru-Soerensen M, Gabrail NY, et al. First-in-class, frst-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors. J Clin Oncol. 2016;34:4142–4150.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Savona M, Baz R, et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood. 2017;129:3175–3183.
   PubMed Web of Science ®Google Scholar
• Gounder MM, Zer A, Tap WD, et al. Phase IB study of selinexor, a frst-in-class inhibitor of nuclear export, in patients with advanced refractory bone of soft tissue sarcoma. J Clin Oncol. 2016;34:3166–3174.
   PubMed Web of Science ®Google Scholar
• Bader JC, Abdul Razak AR, Shacham S, et al. Pharmacokinetics of selinexor: the first-in-class selective inhibitor of nuclear export. Clin Pharmacokinet. 2021 Aug;60(8):957–969. doi: 10.1007/s40262-021-01016-y
   PubMed Web of Science ®Google Scholar
• Garzon R, Savona M, Baz R, et al. A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia. Blood. 2017 Jun 15;129(24):3165–3174.
   PubMed Web of Science ®Google Scholar
• Karyopharm Therapeutics. Data on fle.
   Google Scholar
• Xu H, Li H, Wada R, et al. Selinexor population pharmacokinetic and exposure-response analyses to support dose optimization in patients with diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2021;88(1):69–79. doi: 10.1007/s00280-021-04258-6
   PubMed Web of Science ®Google Scholar
• Chen C, Siegel D, Gutierrez M, et al. Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and waldenstrom macroglobulinemia. Blood. 2018;131(8):855–863. doi: 10.1182/blood-2017-08-797886
   PubMed Web of Science ®Google Scholar
• Vogl DT, Dingli D, Cornell RF, et al. Selective inhibition of nuclear export with oral selinexor for treatment of relapsed or refractory multiple myeloma. J Clin Oncol. 2018;36(9):859–866. doi: 10.1200/JCO.2017.75.5207
   PubMed Web of Science ®Google Scholar
• Yee AJ, Huff CA, Chari A, et al. Response to therapy and the effectiveness of treatment with selinexor and dexamethasone in patients with penta-exposed triple-class refractory myeloma who had plasmacytomas. Blood. 2019;134(Supplement_1):3140. doi: 10.1182/blood-2019-129038
   Google Scholar
• Richardson PG, Jagannath S, Chari A, et al. Overall survival with oral selinexor plus low-dose dexamethasone versus real-world therapy in triple-class-refractory multiple myeloma. EJHaem. 2021;2(1):48–55. doi: 10.1002/jha2.120
   PubMedGoogle Scholar
• Qiu L, Xia Z, Fu C, et al. Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study. BMC Med. 2022;20(1):108. doi: 10.1186/s12916-022-02305-4
   PubMed Web of Science ®Google Scholar
• Bahlis NJ, Sutherland H, White D, et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood. 2018;132(24):2546–2554. doi: 10.1182/blood-2018-06-858852
   PubMed Web of Science ®Google Scholar
• Mateos MV, Engelhardt M, Leleu X, et al. P886: efficacy, survival and safety of selinexor, bortezomib and dexamethasone (SVD) in patients with lenalidomide-refractory multiple myeloma: subgroup data from the Boston trial. Hemasphere. 2023 Aug 8;7(Suppl):e1470834. doi: 10.1097/01.HS9.0000970448.14708.34
   Google Scholar
• Richard S, Chari A, Delimpasi S, et al. Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by cytogenetic risk. Am J Hematol. 2021;96(9):1120–1130. doi: 10.1002/ajh.26261
   PubMed Web of Science ®Google Scholar
• Jagannath S, Delimpasi S, Grosicki S, et al. Association of Selinexor Dose Reductions With Clinical Outcomes in the Boston Study. Clin Lymphoma Myeloma Leuk. 2023 Dec;23(12):917–923.e3. doi: 10.1016/j.clml.2023.08.018
   PubMed Web of Science ®Google Scholar
• Broijl A, Asselbergs EL, Minnena MC, et al. A phase II study of selinexor (KPT-330) combined with bortezomib and dexamethasone (SVd) for induction and consolidation for patients with progressive or refractory multiple myeloma: the SELVEDEX trial. Hemasphere. 2018;2(Supplement 1):1338.
   Google Scholar
• Gasparetto C, Schiller GJ, Tuchman SA, et al. Once weekly selinexor, carfilzomib and dexamethasone in carfilzomib non-refractory multiple myeloma patients. Br J Cancer. 2022;126(5):718–725. doi: 10.1038/s41416-021-01608-2
   PubMed Web of Science ®Google Scholar
• Schiller GJ, Tuchman SA, Callander N, et al. Once weekly selinexor, carfilzomib and dexamethasone (XKd) in triple class refractory multiple myeloma. Blood. 2022;140(Supplement 1):10050–10053. doi: 10.1182/blood-2022-158011
   Google Scholar
• Jakubowiak AJ, Jasielec JK, Rosenbaum CA, et al. Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma. Br J Haematol. 2019;186(4):549–560. doi: 10.1111/bjh.15969
   PubMed Web of Science ®Google Scholar
• Derman BA, Chari A, Zonder J, et al. A phase I study of selinexor combined with weekly carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Eur J Haematol. 2023 May;110(5):564–570. doi: 10.1111/ejh.13937
   PubMed Web of Science ®Google Scholar
• Salcedo M, Lendvai N, Mastey D, et al. Phase I study of selinexor, ixazomib, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2020;20(3):198–200. doi: 10.1016/j.clml.2019.12.013
   PubMed Web of Science ®Google Scholar
• White D, Leblanc R, Venner C, et al. Safety and efficacy of the combination of selinexor, lenalidomide and dexamethasone (SRd) in patients with relapsed/refractory multiple myeloma (RRMM). Clin Lymphoma Myeloma Leuk. 2019;19(10):e55. doi: 10.1016/j.clml.2019.09.084
   Web of Science ®Google Scholar
• White DJ, Chen CI, Baljevic M, et al. Once weekly oral selinexor, pomalidomide, and dexamethasone in relapsed refractory multiple myeloma. Blood. 2021;138(Suppl Supplement 1):2748. doi: 10.1182/blood-2021-148759
   PubMedGoogle Scholar
• Gasparetto C, Lentzsch S, Schiller G, et al. Selinexor, daratumumab, and dexamethasone in patients with relapsed or refractory multiple myeloma. Eur J Haematol. 2021;2:56–65
   Google Scholar
• González-Calle V, Rodríguez-Otero P, Sureda A, et al. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study. Haematologica. 2024 Feb 15. doi: 10.3324/haematol.2023.284089
   PubMedGoogle Scholar
• Sun C, Fang B, Gao G, et al. Interim results of the launch study-a multicenter, open-label study of selinexor, dexamethasone and chemotherapy drugs in relapsed/ refractory multiple myeloma. Blood. 2023;142(Supplement 1):4763.
   Google Scholar
• Baz R, Zonder JA, Shain KH, et al. Phase I/II study of liposomal doxorubicin (DOX) in combination with selinexor (SEL) and dexamethasone (DEX) for relapsed and refractory multiple myeloma (RRMM). Blood. 2017;130:3095.
   Google Scholar
• Nguyen N, Chaudhry S, Totiger TM, et al. Combination venetoclax and selinexor effective in relapsed refractory multiple myeloma with translocation t(11;14). NPJ Precis Oncol. 2022 Oct 19;6(1):73. doi: 10.1038/s41698-022-00315-2
   PubMed Web of Science ®Google Scholar
• Lifen K, Baijun F, Wenming C, et al. Effectiveness and safety of selinexor-based regimens in the treatment of relapsed and refractory multiple myeloma: a multicenter real-world study from China. J Clin Hematol. 2022;35:626–632.
   Google Scholar
• Ahmed N, Wan S, Biran N, et al. Single-center experience of selinexor-based combination therapies for relapsed multiple myeloma. Clin Lymphoma Myeloma Leuk. 2023;23(Supplement 2):224.
   Google Scholar
• Kastritis E, Gavriatopoulou M, Solia E, et al. Real world efficacy and toxicity of selinexor: importance of patient characteristics, dose intensity and post progression outcomes. Clin Lymphoma Myeloma Leuk. 2023 Nov;23(11):844–849. doi: 10.1016/j.clml.2023.07.013
   PubMed Web of Science ®Google Scholar
• Nishihori T, Alsina M, Ochoa J, et al. The result of a phase 1 study of selinexor in combination with high-dose melphalan and autologous hematopoietic cell transplantation for multiple myeloma. Blood. 2019;134(Supplement_1):3314. doi: 10.1182/blood-2019-131321
   Google Scholar
• Chari A, Vogl DT, Jagannath S, et al. Selinexor-based regimens for the treatment of myeloma refractory to chimeric antigen receptor T cell therapy. Br J Haematol. 2020 May;189(4):e126–e130. doi: 10.1111/bjh.16550
   PubMed Web of Science ®Google Scholar
• Baljevic M, Moreau P, Tuchman P, et al. Effectiveness of anti-B-cell maturation antigen (BCMA)-targeting therapy after selinexor treatment. Clin Lymphoma Myeloma Leuk. 2023;23(Supplement 2):1546209.
   Google Scholar
• Neggers JE, Vanstreels E, Baloglu E, et al. Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export. Oncotarget. 2016;7(42):68842. doi: 10.18632/oncotarget.11995
   PubMedGoogle Scholar
• Crochiere M, Kashyap T, Kalid O, et al. Deciphering mechanisms of drug sensitivity and resistance to selective inhibitor of nuclear export (SINE) compounds. BMC Cancer. 2015;15(1):1–22. doi: 10.1186/s12885-015-1790-z
   PubMedGoogle Scholar
• Kang Y, Neff J, Gasparotto C. Investigation of T-cell fitness and mechanisms of drug resistance in selinexor treated patients with relapsed/refractory multiple myeloma - P-396. Clin Lymphoma Myeloma Leuk. 2023;23(Supplement 2):396.
   Google Scholar
• Restrepo P, Bhalla S, Ghodke-Puranik Y, et al. A three-gene signature predicts response to selinexor in multiple myeloma. JCO Precis Oncol. 2022;6:e2200147.
   PubMed Web of Science ®Google Scholar
• Kwanten B, Deconick T, Walker C, et al. E3 ubiquitin ligase ASB8 promotes selinexor-induced proteasomal degradation of XPO1. Biomed Pharmacother. 2023;160:114305.
   PubMed Web of Science ®Google Scholar
• Kendall J, Hall A, Roberts S, et al. MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma. BMJ Open. 2022 Oct 26;12(10):e062504. doi: 10.1136/bmjopen-2022-062504
   PubMed Web of Science ®Google Scholar
• Quach H, Lasica L, Low M, et al. Planned interim safety analysis of the phase 3 randomized trial of selinexor and lenalidomide versus lenalidomide maintenance post autologous stem cell transplant for patients with newly diagnosed multiple myeloma (ALLG MM23; Sealand). Blood. 2023;142(Supplement 1):2023.
   Google Scholar
• A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM, and Seli and Pomalidomide + LDD in Relapsed Refractory MM. https://clinicaltrials.gov/study/NCT04414475
   Google Scholar
• Gavriatopoulou M, Chari A, Chen C, et al. Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. Leukemia. 2020 Sep;34(9):2430–2440. doi: 10.1038/s41375-020-0756-6
   PubMed Web of Science ®Google Scholar
• Machlus KR, Wu SK, Vijey P, et al. Selinexor-induced thrombocytopenia results from inhibition of thrombopoietin signaling in early megakaryopoiesis. Blood. 2017;130(9):1132–1143. doi: 10.1182/blood-2016-11-752840
   PubMed Web of Science ®Google Scholar
• Lonial S, Richardson PG, San Miguel J, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol. 2008;143(2):222–229. doi: 10.1111/j.1365-2141.2008.07321.x
   PubMed Web of Science ®Google Scholar
• Leukemia Expert Committee of Chinese Society of Clinical Oncology. Lymphoma expert committee of chinese society of clinical oncology. Principles for clinical use of selinexor in hematological system diseases (2022 edition). J Leuk Lymphoma. 2023;32:65–73.
   Google Scholar
• Mikhael J, Noonan KR, Faiman B, et al. Consensus recommendations for the clinical management of patients with multiple myeloma treated with selinexor. Clin Lymphoma Myeloma Leuk. 2020 Jun;20(6):351–357. doi: 10.1016/j.clml.2019.12.026
   PubMed Web of Science ®Google Scholar
• Nooka AK, Costa LJ, Gasparetto CJ, et al. Guidance for use and dosing of selinexor in multiple myeloma in 2021: consensus from international myeloma foundation expert roundtable. Clin Lymphoma Myeloma Leuk. 2022;22(7):E526–E531. doi: 10.1016/j.clml.2022.01.014
   PubMed Web of Science ®Google Scholar
• Kala J, Mamlouk O, Jhaveri KD. Selinexor-associated hyponatremia: single-center, real-world data. Kidney Int. 2020;98(3):789–791.
   PubMed Web of Science ®Google Scholar
• Shafique M, Ismail-Khan R, Extermann M, et al. A phase II trial of selinexor (KPT-330) for metastatic triple-negative breast cancer. Oncologist. 2019 Jul;24(7):887–e416.
   PubMed Web of Science ®Google Scholar
• Vergote IB, Lund B, Peen U, et al. Phase 2 study of the Exportin 1 inhibitor selinexor in patients with recurrent gynecological malignancies. Gynecol Oncol. 2020 Feb;156(2):308–314.
   PubMed Web of Science ®Google Scholar
• Lassman AB, Wen PY, van den Bent MJ, et al. A phase II study of the efficacy and safety of oral selinexor in recurrent glioblastoma.Clin Cancer Res. 2022 Feb 1;28(3):452–460. doi: 10.1158/1078-0432.CCR-21-2225
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Price LSL, Okusanya OO, et al. FDA approval summary: selinexor for relapsed or refractory diffuse large b-cell lymphoma. Oncologist. 2021 Oct;26(10):879–886.
   PubMed Web of Science ®Google Scholar
• Schiller GJ, Lipe BC, Bahlis NJ, et al. Selinexor-based triplet regimens in patients with multiple myeloma previously treated with anti-CD38 monoclonal antibodies. Clin Lymphoma Myeloma Leuk. 2023 Sep;23(9):e286–e296.e4. doi: 10.1016/j.clml.2023.06.001
   PubMed Web of Science ®Google Scholar
• Mateos MV, Gavriatopoulou M, Facon T, et al. Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. J Hematol Oncol. 2021 Apr 13;14(1):59. doi: 10.1186/s13045-021-01071-9
   PubMed Web of Science ®Google Scholar
• Richter J, Zonder JA, Nathwani N, et al. Selinexor, ixazomib, pomalidomide and dexamethasone in functionally high-risk multiple myeloma: results from the myeloma developing regimens using genomics (MyDRUG) sub-protocol Y3. Blood. 2023;142(Supplement 1):3387.
   Google Scholar
• Etchin J, Berezovskaya A, Conway AS, et al. KPT-8602, a second-generation inhibitor of XPO1-mediated nuclear export, is well tolerated and highly active against AML blasts and leukemia-initiating cells. Leukemia. 2017;31(1):143–150. doi: 10.1038/leu.2016.145.
   PubMed Web of Science ®Google Scholar
• Turner JG, Dawson JL, Cubitt CL, et al. Next generation XPO1 inhibitor KPT-8602 for the treatment of drug-resistant multiple myeloma. Blood. 2015;126(23):1818. doi: 10.1182/blood.V126.23.1818.1818
   Google Scholar
• Cornell RF, Rossi AC, Baz R, et al. Eltanexor (KPT-8602), a second-generation selective inhibitor of nuclear export (SINE) compound, in patients with refractory multiple myeloma. Blood. 2017;130:3134.
   Web of Science ®Google Scholar
• Munshi NC, LD A Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. doi: 10.1056/NEJMoa2024850
   PubMed Web of Science ®Google Scholar
• Berdeja JG, Madduri D, Usmani SZ, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398(10297):314–324. doi: 10.1016/S0140-6736(21)00933-8
   PubMed Web of Science ®Google Scholar
• Cengiz G, Karakaya B, Yilmaz H, et al. Comparison of salvage autologous hematopoietic cell transplantation with outcomes following selinexor combinations among double/triple refractory myeloma patients. Blood. 2021;138(Supplement 1):4904. doi: 10.1182/blood-2021-148835
   Google Scholar
• Parrondo RD, Sam K, Rasheed A, et al. Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: a single center analysis. Blood Cancer J. 2022 Apr 19;12(4):66.
   PubMed Web of Science ®Google Scholar
• Baljevic M, Gasparetto C, Schiller GJ, et al. Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment. EJHaem. 2022 Sep 30;3(4):1270–1276. doi: 10.1002/jha2.572
   PubMedGoogle Scholar
• Zhou H, Chang L, Jia J, et al. Renal response of selinexor, pomalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients with renal impairment: a prospective, open-label, multicenter, phase 2 study. Blood. 2023;142(Supplement 1):4754.
   Google Scholar